{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:55:47Z","timestamp":1764251747430,"version":"3.44.0"},"reference-count":12,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:sec>\n          <jats:title>OBJECTIVE<\/jats:title>\n          <jats:p>To determine the incidence of cytomegalovirus (CMV) DNAemia and disease, identify potential risk factors, and assess the safety and efficacy of weight-based valganciclovir dosing in pediatric post\u2013renal transplant patients.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>METHODS<\/jats:title>\n          <jats:p>This single-center, retrospective study included patients \u226421 years who received a kidney transplant between January 1, 2011, and November 1, 2019, with 3 to 24 months of follow-up data. Demographics and clinical characteristics were collected to assess for potential risk factors. Descriptive statistics and logistic regressions were used to determine rates of CMV DNAemia considering clinical characteristics and chemoprophylaxis.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>RESULTS<\/jats:title>\n          <jats:p>Fifty-seven patients were included. The incidence of CMV DNAemia was 43.9%. Cytomegalovirus seropositive status was associated with increased risk of CMV DNAemia. Patients receiving valganciclovir for &lt;150 days had 8.33 (95% CI, 1.68\u201341.29) greater odds of developing CMV DNAemia than patients receiving valganciclovir for 180 \u00b1 30 days, p = 0.01. The median time to detectable CMV PCR after transplant was 140 days (range, 12\u2013511 days). Cytomegalovirus DNAemia was not statistically different between those receiving weight-based vs FDA-approved valganciclovir dosing; however, patients receiving the FDA-approved dosing were more likely to develop neutropenia. Among the intermediate-risk group, the adjusted relative risk of CMV DNAemia was 0.62 (95% CI, 0.36\u20131.09) for those not receiving chemoprophylaxis compared with those who did.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>CONCLUSIONS<\/jats:title>\n          <jats:p>Risk of CMV DNAemia is higher among patients receiving valganciclovir for &lt;150 days. Further exploration of weight-based valganciclovir dosing for CMV chemoprophylaxis in high- and intermediate-risk post\u2013renal transplant patients is needed to minimize adverse drug effects while maintaining efficacy.<\/jats:p>\n        <\/jats:sec>","DOI":"10.5863\/1551-6776-27.2.164","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T22:41:33Z","timestamp":1644446493000},"page":"164-171","source":"Crossref","is-referenced-by-count":4,"title":["Incidence of Cytomegalovirus DNAemia in Pediatric Post\u2013Renal Transplant Patients Receiving Weight-Based vs Body Surface Area\u2013Based Valganciclovir Chemoprophylaxis"],"prefix":"10.5863","volume":"27","author":[{"given":"Amber N.","family":"Thomas","sequence":"first","affiliation":[{"name":"Office of Experiential Education (ANT), University of Oklahoma College of Pharmacy, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phu B.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Pharmacy Department (PBN), OU Health, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie L.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy: Clinical and Administrative Sciences (JLM, TVL), University of Oklahoma College of Pharmacy, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Neely","sequence":"additional","affiliation":[{"name":"Office of Instructional Science and Assessment (SBN), University of Oklahoma College of Pharmacy, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa V.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy: Clinical and Administrative Sciences (JLM, TVL), University of Oklahoma College of Pharmacy, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"8","key":"i2331-348X-27-2-164-b1","series-title":"Transplantation","first-page":"1391","article-title":"Incidence of cytomegalovirus DNAemia in pediatric kidney transplant recipients after cessation of antiviral prophylaxis","volume":"102","year":"2018","unstructured":"Chaiyapak\n              T,\n            \n            \n              Borges\n              K,\n            \n            \n              Williams\n              A,\n            \n          \n          .\n\t\t\t\t\tIncidence of cytomegalovirus DNAemia in pediatric kidney transplant recipients after cessation of antiviral prophylaxis.\n\t\t\t\t\tTransplantation.\n\t\t\t\t\t2018;\n\t\t\t\t\t102(\n\t\t\t\t\t8):\n\t\t\t\t\t1391\u2013\n\t\t\t\t\t1396."},{"issue":"4","key":"i2331-348X-27-2-164-b2","series-title":"Transplantation","first-page":"862","article-title":"Cytomegalovirus infection in pediatric renal transplantation and the impact of the chemoprophylaxis with (val-)ganciclovir","volume":"100","year":"2016","unstructured":"H\u00f6cker\n              B,\n            \n            \n              Zencke\n              S,\n            \n            \n              Krupka\n              K,\n            \n          \n          .\n\t\t\t\t\tCytomegalovirus infection in pediatric renal transplantation and the impact of the chemoprophylaxis with (val-)ganciclovir.\n\t\t\t\t\tTransplantation.\n\t\t\t\t\t2016;\n\t\t\t\t\t100(\n\t\t\t\t\t4):\n\t\t\t\t\t862\u2013\n\t\t\t\t\t870."},{"issue":"9","key":"i2331-348X-27-2-164-b3","series-title":"J Am Soc Nephrol","first-page":"1579","article-title":"Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation","volume":"21","year":"2010","unstructured":"Smith\n              JM,\n            \n            \n              Corey\n              L,\n            \n            \n              Bittner\n              R,\n            \n          \n          .\n\t\t\t\t\tSubclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation.\n\t\t\t\t\tJ Am Soc Nephrol.\n\t\t\t\t\t2010;\n\t\t\t\t\t21(\n\t\t\t\t\t9):\n\t\t\t\t\t1579\u2013\n\t\t\t\t\t1586."},{"issue":"9","key":"i2331-348X-27-2-164-b4","series-title":"Clin Transplant","first-page":"e13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","year":"2019","unstructured":"Razonable\n              RR,\n            \n            \n              Humar\n              A.\n            \n          \n          Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.\n\t\t\t\t\tClin Transplant.\n\t\t\t\t\t2019;\n\t\t\t\t\t33(\n\t\t\t\t\t9):\n\t\t\t\t\te13512."},{"issue":"suppl 1","key":"i2331-348X-27-2-164-b5","series-title":"Am J Transplant","first-page":"20","article-title":"OPTN\/SRTR 2018 annual data report: kidney","volume":"20","year":"2020","unstructured":"Hart\n              A,\n            \n            \n              Smith\n              JM,\n            \n            \n              Skeans\n              MA,\n            \n          \n          .\n\t\t\t\t\tOPTN\/SRTR 2018 annual data report: kidney.\n\t\t\t\t\tAm J Transplant.\n\t\t\t\t\t2020;\n\t\t\t\t\t20(\n\t\t\t\t\tsuppl 1):\n\t\t\t\t\t20\u2013\n\t\t\t\t\t130."},{"issue":"2","key":"i2331-348X-27-2-164-b6","series-title":"Transplantation","first-page":"245","article-title":"24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience","volume":"91","year":"2011","unstructured":"Camacho-Gonzalez\n              AD,\n            \n            \n              Gutman\n              J,\n            \n            \n              Hymes\n              LC,\n            \n          \n          .\n\t\t\t\t\t24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience.\n\t\t\t\t\tTransplantation.\n\t\t\t\t\t2011;\n\t\t\t\t\t91(\n\t\t\t\t\t2):\n\t\t\t\t\t245\u2013\n\t\t\t\t\t250."},{"issue":"3","key":"i2331-348X-27-2-164-b7","series-title":"J Am Soc Nephrol","first-page":"629","article-title":"New equations to estimate GFR in children with CKD","volume":"20","year":"2009","unstructured":"Schwartz\n              GJ,\n            \n            \n              Munoz\n              A,\n            \n            \n              Schneider\n              MF,\n            \n          \n          .\n\t\t\t\t\tNew equations to estimate GFR in children with CKD.\n\t\t\t\t\tJ Am Soc Nephrol.\n\t\t\t\t\t2009;\n\t\t\t\t\t20(\n\t\t\t\t\t3):\n\t\t\t\t\t629\u2013\n\t\t\t\t\t637."},{"issue":"1","key":"i2331-348X-27-2-164-b8","series-title":"Pediatr Transplant","first-page":"e12816","article-title":"The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children","volume":"21","year":"2017","unstructured":"Cameron\n              BM,\n            \n            \n              Kennedy\n              SE,\n            \n            \n              Rawlinson\n              WD,\n            \n            \n              Mackie\n              FE.\n            \n          \n          The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.\n\t\t\t\t\tPediatr Transplant.\n\t\t\t\t\t2017;\n\t\t\t\t\t21(\n\t\t\t\t\t1):\n\t\t\t\t\te12816."},{"issue":"8","key":"i2331-348X-27-2-164-b9","series-title":"Pediatr Infect Dis J","first-page":"745","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients","volume":"36","year":"2017","unstructured":"Peled\n              O,\n            \n            \n              Berkovitch\n              M,\n            \n            \n              Rom\n              E,\n            \n          \n          .\n\t\t\t\t\tValganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2017;\n\t\t\t\t\t36(\n\t\t\t\t\t8):\n\t\t\t\t\t745\u2013\n\t\t\t\t\t750."},{"key":"i2331-348X-27-2-164-b10","article-title":"International Statistical Classifications of Diseases and Related Health Problems, 10th Revision (ICD-10)","volume":"Volume 3","year":"2005","unstructured":"International Statistical Classifications of Diseases and Related Health Problems, 10th Revision (ICD-10).\n\t\t\t\t\tVolume 3.\n\t\t\t\t\tSecond edition.\n\t\t\t\t\tGeneva,\n\t\t\t\t\tWorld Health Organization;\n\t\t\t\t\t2005."},{"issue":"1","key":"i2331-348X-27-2-164-b11","series-title":"Pediatr Transplant","first-page":"80","article-title":"Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients","volume":"17","year":"2013","unstructured":"Villeneuve\n              D,\n            \n            \n              Brothers\n              A,\n            \n            \n              Harvey\n              E,\n            \n          \n          .\n\t\t\t\t\tValganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.\n\t\t\t\t\tPediatr Transplant.\n\t\t\t\t\t2013;\n\t\t\t\t\t17(\n\t\t\t\t\t1):\n\t\t\t\t\t80\u2013\n\t\t\t\t\t85."},{"issue":"3","key":"i2331-348X-27-2-164-b12","series-title":"CPT Pharmacometrics Syst Pharmacol","first-page":"167","article-title":"Pediatric dosing of ganciclovir and valganciclovir: how model-based simulations can prevent underexposure and potential treatment failure","volume":"8","year":"2019","unstructured":"Jorga\n              K,\n            \n            \n              Reigner\n              B,\n            \n            \n              Chavanne\n              C,\n            \n          \n          .\n\t\t\t\t\tPediatric dosing of ganciclovir and valganciclovir: how model-based simulations can prevent underexposure and potential treatment failure.\n\t\t\t\t\tCPT Pharmacometrics Syst Pharmacol.\n\t\t\t\t\t2019;\n\t\t\t\t\t8(\n\t\t\t\t\t3):\n\t\t\t\t\t167\u2013\n\t\t\t\t\t176."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/2\/article-p164.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/2\/164\/3108315\/i2331-348x-27-2-164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/2\/article-p164.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/2\/article-p164.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:36:16Z","timestamp":1747355776000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/2\/article-p164.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":12,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.2.164","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2022]]}}}